Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, pursuant to the Answer of 7 November 2016 to Question 51102, on Dense Deposit Disease: eculizumab, when he plans for the new policy proposition for the use of eculizumab in treating Dense Deposit Disease before a patient has had a kidney transplant to be considered during 2017; and when the Clinical Priorities Advisory Group will report on its consideration of the policy on the treatment of C3 glomerulopathy after kidney transplant.

The Clinical Priorities Advisory Group (CPAG) considered the policy proposition on the treatment of C3 glomerulopathy after kidney transplant in November 2016 but this was not supported, primarily on the grounds of affordability. It was agreed that this policy would be given further consideration by CPAG in spring 2017.

A policy proposition for pre-transplant patients to receive eculizumab was considered by the NHS England Specialised Commissioning Clinical Panel in December 2016. The Clinical Panel concluded there was insufficient evidence to support development of a policy and, therefore, this topic will not enter the policy work programme at this stage. NHS England will liaise with the National Institute for Health Research to discuss the potential for an international clinical group to develop an international trial.